Clinical trials: sponsored by Jonsson Comprehensive Cancer Center
Lymphoma
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00020800
- Testing
- rituximab, fludarabine phosphate
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00098462
- Testing
- gefitinib, sirolimus
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00093769
- Testing
- bortezomib + rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Depression, Fatigue
Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer
RATIONALE: Measuring levels of interleukin-6 and depression may help doctors understand the relationship between interleukin-6 and depression. It may also help the study of cancer in the future.
- Conditions
- Depression, Fatigue, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00460200
- Testing
- polymorphism analysis, laboratory biomarker analysis, physiologic testing
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
BMS-599626 in Treating Patients With Metastatic Solid Tumors
RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with…
- Trial name
- NCT00093730
- Testing
- BMS-59926
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors
RATIONALE: New imaging procedures, such as functional magnetic resonance imaging and 1H-nuclear magnetic resonance spectroscopic imaging, may improve the ability to detect the extent of cancer in the brain.
- Trial name
- NCT00005083
- Testing
- conventional surgery, magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer, Inflammation
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.
- Trial name
- NCT01180907
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Autoimmune Diseases, Cancer
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune…
- Trial name
- NCT01180868
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
Prostate cancer is prevalent in the United States, with approximately 230,110 new cases and 29,900 deaths in 2004. Approximately 30% of new cases will be clinical stage T3 when they are diagnosed.
- Trial name
- NCT00790595
- Testing
- SU011248
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Renal Cell Carcinoma
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
This study is designed to explore the molecular modulatory effect of Sunitinib when given in a neoadjuvant setting prior to radical or partial nephrectomy.
- Trial name
- NCT01070186
- Testing
- Sunitinib, Tumor biopsy, Nephrectomy
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
RATIONALE: BMS-354825 and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00112775
- Testing
- dasatinib, imatinib mesylate
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Head and Neck Cancer
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004865
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation.
- Trial name
- NCT00003409
- Testing
- motexafin gadolinium, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00098917
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center